QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)

Intercept Pharmaceuticals (ICPT) Stock Forecast & Price Target

Notice: This company has been marked as potentially delisted and may not be actively trading.

Intercept Pharmaceuticals Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 8 Analyst Ratings

Analysts' Consensus Price Target

$23.18
22.01% Upside
High Forecast$54.00
Average Forecast$23.18
Low Forecast$14.00
TypeCurrent Forecast
3/1/23 to 2/29/24
1 Month Ago
1/30/23 to 1/30/24
3 Months Ago
12/1/22 to 12/1/23
1 Year Ago
3/1/22 to 3/1/23
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
4 Buy rating(s)
Hold
7 Hold rating(s)
7 Hold rating(s)
7 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$23.18$23.18$23.18$26.00
Predicted Upside22.01% Upside30.83% Upside30.83% Upside65.09% Upside
Get Intercept Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ICPT and its competitors with MarketBeat's FREE daily newsletter.


ICPT Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ICPT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Intercept Pharmaceuticals Stock vs. The Competition

TypeIntercept PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.13
2.68
2.48
Consensus RatingHoldModerate BuyHold
Predicted Upside22.01% Upside1,863.06% Upside7.19% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/27/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetSector Perform ➝ Sector Perform$12.00 ➝ $19.00+1.55%
9/27/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold$20.00 ➝ $19.00+1.55%
9/27/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Arce
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$19.00+1.55%
9/26/2023B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Mamtani
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$15.00 ➝ $19.00+1.71%
5/23/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$17.00 ➝ $14.00+46.90%
5/23/2023Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
5/22/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$35.00 ➝ $18.00+32.74%
5/17/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
4/10/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$49.00 ➝ $54.00+255.26%
3/3/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform$17.00 ➝ $18.00-12.15%
3/3/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$17.00 ➝ $18.00-12.54%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 08:12 PM ET.












ICPT Price Target - Frequently Asked Questions

What is Intercept Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 8 analysts in the last year, the consensus rating for Intercept Pharmaceuticals stock is Hold based on the current 7 hold ratings and 1 buy rating for ICPT. The average twelve-month price prediction for Intercept Pharmaceuticals is $23.18 with a high price target of $54.00 and a low price target of $14.00. Learn more on ICPT's analyst rating history.

Do Wall Street analysts like Intercept Pharmaceuticals more than its competitors?

Analysts like Intercept Pharmaceuticals less than other Medical companies. The consensus rating for Intercept Pharmaceuticals is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how ICPT compares to other companies.

Does Intercept Pharmaceuticals's stock price have much upside?

According to analysts, Intercept Pharmaceuticals's stock has a predicted upside of 30.83% based on their 12-month stock forecasts.


Stock Ratings Reports and Tools

This page (NASDAQ:ICPT) was last updated on 2/29/2024 by MarketBeat.com Staff